Compugen

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees and has raised a total of $141.92 million across 7 funding rounds from 3 investors. The company went public on NASDAQ in August 2000 and on TASE in January 2002.

Business overview

Compugen is a clinical-stage drug discovery and development company specializing in oncology and immunology, with a focus on immuno-oncology. The company leverages a predictive-discovery infrastructure to advance a therapeutic pipeline of early-stage immuno-oncology programs. These programs aim to harness the immune system to eradicate cancer, based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates. Compugen's technology is designed to provide cancer immunotherapies addressing unmet needs in various cancer types and patient populations, both as monotherapies and in combination. The company also expanded its discovery capabilities to include myeloid target candidates within the tumor microenvironment, serving the pharmaceutical and healthcare industries.

Strategic signal

In October 2025, Compugen is scheduled to present at SITC 2025, highlighting its ongoing commitment to advancing predictive computational drug target discovery. This consistent presence at key scientific conferences signals the company's continued focus on research and development, aiming to validate its pipeline and attract further scientific and investor interest in its immuno-oncology programs.

Company Intelligence Q&A

What is Compugen's primary focus in drug discovery?

Compugen specializes in clinical-stage drug discovery and development, with a primary focus on oncology and immunology, particularly immuno-oncology, utilizing a predictive-discovery infrastructure.

When did Compugen go public?

Compugen went public on NASDAQ in August 2000 and on TASE in January 2002.

What was a significant recent intellectual property expansion for Compugen?

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any Anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.

What clinical data did Compugen present in November 2023?

In November 2023, Compugen presented data indicating that its COM701 (anti-PVRIG) mediates anti-tumor activity in patients typically not responding to immunotherapy.